Universiteit Leiden

nl en

Adam Cohen

Name
Prof.dr. A.F. Cohen
Telephone
+31 71 526 9111
E-mail
ac@chdr.nl

Adam Cohen in Professor of Clinical Pharmacology and was until 2018 CEO of the Foundation Centre for Human Drug Research (www.chdr.nl). CHDR is a leading institute involved in early drug research in collaboration with LUMC and Leiden University. He is a physician at the department of Nephrology of LUMC.

More information about Adam Cohen

Adam Cohen in Professor of Clinical Pharmacology and was until 2018 CEO of the Foundation Centre for Human Drug Research (www.chdr.nl). CHDR is a leading institute involved in early drug research in collaboration with LUMC and Leiden University. He is a physician at the department of Nephrology of LUMC.

He is Editor-in-Chief of the British Journal of Clinical Pharmacology. Between 1999 and 2011 he was vice-chairman of the Netherlands Competent Authority for Human Research (CCMO) and as such responsible for the formation of the regulatory policy for research in humans. He is a member of the supervisory Board of the Rotterdam Eye hospital and a member of the Scientific Advisory Council of the German Institute for Aerospace Research and active in several international committees for scientific advice. He is the current recipient of the Lilly Prize of the British Pharmacological Society. He is also active in several organizations for music and theater in Leiden.

Clinical Pharmacology

Clinical Pharmacologists study the effects of medicines in humans. All doctors no matter if they are surgeons or physicians use medicines when they treat patients so this knowledge is of importance in the whole field. Finding new medicines is necessary because there are still many diseases that are not treatable optimally. CHDR is involved in the study of medicines for virtually all therapeutic areas. Additionally methodology is required to measure the effects of medicines accurately. Studying new medicines and measuring their effects with innovative methodology are the hallmarks of the research at CHDR. New wearable devices allow these measurements to take place in the home of the patient and the Trial@home program is an important feature of the research at CHDR. Perhaps more important that the research is the education of undergraduate and postgraduate medical students who learn how medicines work and how they should usewith these potentially dangerous substances safely in patients.

Academic career

Adam Cohen studies pharmacy and medicine in Leiden and worked subsequently in the department of Clinical Pharmacology of the Wellcome Research Laboratories and the department of internal medicine of King’s College Hospital in Londen , UK. His PhD was in Leiden on May 29th with Professor Douwe Breimer. After his return to the Netherlands in 1987 he became CEO of the Centre for Human Drug Research which he led until 2018. During this period the organization grew to a size of 300 staff. His public lecture as Professor of Clinical Pharmacology was on March 31st 1995 and he will be in this position until November 9th 2018. From 1-1 2018 he is Director Innovation Services (InnoS) at CHDR involved in advice on drug development and innovative methods for evaluation of drug effects. He is one of the founders of the Leiden Paul Janssen FutureLab, an educational institute for researchers who aspire to develop health care interventions. 

  • Faculteit Geneeskunde
  • LUMC - Medische Faculteit Leiden
  • Faculteit algemeen

Work address

LUMC Main Building
Albinusdreef 2
2333 ZA Leiden

Contact

Professor of Clinical pharmacology

  • Wiskunde en Natuurwetenschappen
  • Leiden Academic Centre for Drug Research
  • LACDR/Algemeen

Publications

  • Britisch Journal of Clinical Pharmacology Editor in Chief
  • Diabetes vereniging Wetenschappelijke adviesraad
  • Gezondheidsraad Lid
  • KNAW Raad medische wetenschappen
  • Nationale Wetenschaps Foundation Zwitserland Wetenschappelijke adviesraad
  • Omnicom inc Fort Lauderdale Non Executive Board Member
  • Oogziekenhuis Rotterdam Raad van Toezicht
  • Stichting CHDR Algemeen bestuurder

This website uses cookies. Read more